News Related to Ligand Pharmaceuticals

Related coverage linked through entity extraction aliases.

Arecor seeks broader AT278 partnership as phase II trial start is targeted for 2026

Apr 13, 2026

Arecor said it is in talks on a broader AT278 partnership as it targets a phase II trial start in the second half of 2026. The company also cited FDA feedback, Ligand financing and year-end cash of £6.1 million.

Ligand Pharmaceuticals to Report Q4 and Full Year 2025 Results Amid Share Price Volatility

Feb 12, 2026

Ligand Pharmaceuticals will release Q4 and full year 2025 financial results on February 26, 2026, following recent share price declines despite strong annual returns. The company reported annual revenue of $251.233 million and net income of $48.581 million.